echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Severe protection rate of 96%, Cansino adenovirus vector new crown vaccine phase III clinical results announced

    Severe protection rate of 96%, Cansino adenovirus vector new crown vaccine phase III clinical results announced

    • Last Update: 2022-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, CanSino Biological Co.
    , Ltd.
    issued an announcement stating that its phase III clinical trial of recombinant new coronavirus vaccine (type 5 adenovirus vector, Ad5-nCoV, trade name: Keweisha) has made the latest progress
    .
    This international multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluated the effectiveness, safety, and immunogenicity of a single dose of Kevisa in adults 18 years and older
    .
    The results of the study showed that a single dose of Kevisa showed 57.
    5% effectiveness in preventing symptomatic COVID-19 disease 28 days after vaccination and 91.
    7% in preventing severe diseases; 14 days after vaccination, it was effective in preventing symptomatic COVID-19 disease.
    COVID-19 disease showed 63.
    7% effectiveness and 96.
    0% effectiveness in preventing severe diseases
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.